Open access
Open access
Powered by Google Translator Translator

Interventional Cardiology

PCI vs. CABG in left main coronary disease patients with and without diabetes—a pooled analysis of 4 trials

22 Mar, 2024 | 11:41h | UTC

Study Design and Population: This research pooled individual patient data from four randomized clinical trials (SYNTAX, PRECOMBAT, NOBLE, and EXCEL), comparing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in 4393 patients with left main coronary artery disease. The trials included both patients with and without diabetes, allowing for a comparative analysis of outcomes based on the revascularization method and the presence of diabetes.

Main Findings: Patients with diabetes exhibited higher rates of 5-year mortality, spontaneous myocardial infarction (MI), and repeat revascularization compared to those without diabetes. However, mortality rates following PCI vs. CABG were similar in diabetic (15.3% vs. 14.1%, respectively) and non-diabetic patients (9.7% vs. 8.9%, respectively). PCI was associated with a lower risk of stroke within the first year post-operation across all patients. Notably, diabetic patients underwent higher rates of spontaneous MI and repeat revascularization after PCI compared to CABG, with a more significant absolute excess risk observed beyond the first year compared to non-diabetic patients.

Implications for Practice: For patients with left main disease deemed suitable for either PCI or CABG, diabetes status significantly influences long-term outcomes, including death and cardiovascular events. While PCI offers a lower early risk of stroke, it is associated with increased risks of spontaneous MI and repeat revascularization, particularly in diabetic patients. These findings underscore the importance of considering patient-specific factors, such as diabetes status, in choosing between PCI and CABG for left main coronary artery disease revascularization.

Reference

Prakriti Gaba et al. (2024). Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials. Circulation, 0. DOI: 10.1161/CIRCULATIONAHA.123.065571. Access the study here: Link


Meta-Analysis: No mortality benefit of early vs. delayed/selective coronary angiography in out-of-hospital cardiac arrest without ST-elevation

21 Mar, 2024 | 11:40h | UTC

Study Design and Population: This article presents a systematic review and meta-analysis of five randomized controlled trials comparing early/immediate versus delayed/selective coronary angiography (CAG) in 1512 patients who experienced out-of-hospital cardiac arrest (OHCA) without ST-segment elevation. The population had a mean age of 67 years, with 26% female and 23% having a prior myocardial infarction. Follow-up duration was at least 30 days across included studies.

Main Findings: The analysis revealed no significant difference in the odds of all-cause death between early/immediate and delayed/selective CAG strategies (Odds Ratio [OR] 1.12, 95% CI 0.91–1.38). Similar results were found for the composite outcome of all-cause death or neurological deficit (OR 1.10, 95% CI 0.89–1.36). Subgroup analysis showed no significant effect modification based on age, initial cardiac rhythm, history of coronary artery disease, the presumed ischemic cause of arrest, or time to return of spontaneous circulation. Interestingly, a trend toward increased odds of death was observed in women receiving early CAG compared to men, although this finding approached but did not reach statistical significance.

Implications for Practice: The findings suggest that for OHCA patients without ST-segment elevation, an early/immediate CAG strategy does not confer a mortality benefit over a delayed/selective approach across major subgroups. Notably, the potential for increased mortality risk in women with early CAG warrants further investigation. Clinicians should consider these results when deciding on the timing of CAG in this patient population, keeping in mind the overall lack of mortality benefit and the nuanced differences among subgroups.

Reference: Fardin Hamidi et al. (2023). Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials. Clinical Research in Cardiology, 113(561–569). Access the study here: [Link]


Review | An approach to non-left main bifurcation lesions

11 Aug, 2023 | 15:22h | UTC

An Approach to Non-left Main Bifurcation Lesions: A Contemporary Review – US Cardiology Review

 

Commentary on Twitter

 


Review | Interventional cardio-oncology: unique challenges and considerations in a high-risk population

8 Aug, 2023 | 13:27h | UTC

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population – Current Treatment Options in Oncology

 


Expert Panel | Assessment and management of older adults undergoing percutaneous coronary intervention

7 Aug, 2023 | 14:55h | UTC

Assessment and Management of Older Adults Undergoing PCI, Part 1: A JACC: Advances Expert Panel – Journal of the American College of Cardiology

A Geriatric Approach to Percutaneous Coronary Interventions in Older Adults, Part II: A JACC: Advances Expert Panel – Journal of the American College of Cardiology

 


Perspective | The most important trial in modern cardiology (Critical appraisal of the ISCHEMIA trial)

2 Aug, 2023 | 14:11h | UTC

Chapter 3: The Most Important Trial in Modern Cardiology – Sensible Medicine

See also:

Chapter 1: What Does it Mean to Discover a Coronary Blockage? – By Dr John Mandrola

Chapter 2: On the meaning of a coronary blockage – By Dr John Mandrola

Related/Original Articles:

ISCHEMIA Trial: Health-Status Outcomes with Initial Invasive vs. Conservative Care in Stable Coronary Disease

ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease

ISCHEMIA Trial: Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease

ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease

Follow-up of the ISCHEMIA trial | Similar survival after invasive vs. conservative management of stable coronary disease.

ISCHEMIA Trial 2ry Analysis | Patients with CCD and daily/weekly angina seem to benefit most from complete revascularization

 


2023 AHA/ACC clinical performance and quality measures for coronary artery revascularization

31 Jul, 2023 | 14:31h | UTC

2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures – Journal of the American College of Cardiology

News Release: New Coronary Artery Revascularization Clinical Performance and Quality Measures Released – American College of Cardiology

Key Points: 2023 Clinical Performance Measures for Coronary Revascularization – American College of Cardiology

Commentary: New AHA/ACC Performance and Quality Metrics for Coronary Revascularization – TCTMD

 


ISCHEMIA Trial 2ry Analysis | Patients with CCD and daily/weekly angina seem to benefit most from complete revascularization

26 Jul, 2023 | 13:33h | UTC

Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentaries:

Complete Revascularization and Angina-Related Health Status – American College of Cardiology

More Angina Relief With Complete Revascularization in Stable CAD: ISCHEMIA – TCTMD

Related/Original Articles:

Follow-up of the ISCHEMIA trial | Similar survival after invasive vs. conservative management of stable coronary disease.

ISCHEMIA Trial: Health-Status Outcomes with Initial Invasive vs. Conservative Care in Stable Coronary Disease

ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease

ISCHEMIA Trial: Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease

ISCHEMIA Trial: Management of Coronary Disease in Patients with Advanced Kidney Disease

 


Perspective | What does it mean to discover a coronary blockage?

26 Jul, 2023 | 13:31h | UTC

Chapter 1: What Does it Mean to Discover a Coronary Blockage? – By Dr John Mandrola

Chapter 2: On the meaning of a coronary blockage – By Dr John Mandrola

 


M-A | P2Y12 monotherapy after 1-3 months DAPT safely reduces bleeding in PCI patients with CAD and CKD

26 Jul, 2023 | 13:18h | UTC

P2y12 inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials – Frontiers in Cardiovascular Medicine

Related:

De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis – Nature Reviews Cardiology (if the link is paywalled, try this one)

RCT | 3-6 month DAPT noninferior to 12 month DAPT in patients undergoing PCI with third-generation DES

Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes – JACC: Cardiovascular Interventions

Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial – JAMA

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial – JAMA

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial – JAMA Cardiology

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial – The BMJ

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial – The Lancet

Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting – Journal of the American College of Cardiology

 


Consensus Paper | De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and PCI

24 Jul, 2023 | 13:08h | UTC

De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis – Nature Reviews Cardiology (if the link is paywalled, try this one)

 


RCT | Half-dose Tenecteplase + later PCI if indicated seems to be viable option in older individuals when timely PCI is unavailable

21 Jul, 2023 | 13:36h | UTC

Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial – Circulation (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Review | Guiding the use of invasive cardiac interventions in patients with advanced malignancies

17 Jul, 2023 | 13:23h | UTC

Invasive Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: A Conceptual Framework: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


Review | Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation

27 Jun, 2023 | 13:33h | UTC

Functional coronary angiography for the assessment of the epicardial vessels and the microcirculation – EuroIntervention

 

Commentary on Twitter

 


M-A | Similar death rates in left main disease patients treated with PCI or CABG, both in patients with and without ACS

15 Jun, 2023 | 14:59h | UTC

Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials – JAMA Cardiology (link to abstract – $ for full-text)

Commentary: CABG and PCI Comparable in ACS Patients With Left Main CAD – TCTMD

 


Consensus Statement | Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging

13 Jun, 2023 | 13:49h | UTC

Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group – Nature Reviews Cardiology (if the link is paywalled, try this one)

 

Commentary on Twitter

 


Consensus Paper | Applied coronary physiology for planning and guidance of percutaneous coronary interventions

30 May, 2023 | 11:58h | UTC

Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology – EuroIntervention

 


Review | Bail-out techniques in percutaneous intervention for Ellis Grade III coronary perforation in left main distal bifurcation lesions

29 May, 2023 | 10:51h | UTC

Bail-Out Techniques in Percutaneous Intervention for Ellis Grade III Coronary Perforation in Left Main Distal Bifurcation Lesions – JSCAI

 

Commentary on Twitter

 


SCAI Consensus Statement | Management of in-stent restenosis and stent thrombosis

22 May, 2023 | 13:41h | UTC

SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis – Journal of the Society for Cardiovascular Angiography & Interventions

News Release: Guidance on management of in-stent restenosis and stent thrombosis – Society for Cardiovascular Angiography and Interventions

 


Stent angioplasty in coronary artery anomalies with intramural course: when, why, how, with what results?

16 May, 2023 | 14:38h | UTC

Stent Angioplasty in Coronary Artery Anomalies With Intramural Course: When, Why, How, With What Results? – Journal of the Society for Cardiovascular Angiography & Interventions

 

Commentary on Twitter

 


Review | Dilemmas in cardiology: when to recanalize a chronic total occlusion

12 May, 2023 | 13:19h | UTC

Dilemmas in cardiology: when to recanalize a chronic total occlusion – European Heart Journal Supplements

See all articles in the series here


M-A | PCI vs. CABG in non–ST-elevation coronary syndromes and multivessel disease

10 May, 2023 | 15:35h | UTC

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Non–ST-Elevation Coronary Syndromes and Multivessel Disease: A Systematic Review and Meta-Analysis – American Journal of Cardiology

 


Expert Panel | Appropriate use criteria for the management of aortic stenosis

5 May, 2023 | 15:22h | UTC

Appropriate Use Criteria for the Management of Aortic Stenosis: Insight From the Japanese Expert Panel – JACC: Asia

 


Contemporary percutaneous management of coronary calcification: current status and future directions

18 Apr, 2023 | 13:06h | UTC

Contemporary percutaneous management of coronary calcification: current status and future directions – OpenHeart

 


Single arm trial | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography

12 Apr, 2023 | 13:06h | UTC

Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial – Cardiovascular Diabetology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.